

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

CD279 (PD-1)

RRID:AB_2738543

Type: Antibody

Proper Citation

BD Biosciences Cat# 564017, RRID:AB_2738543

Antibody Information

URL: http://antibodyregistry.org/AB_2738543

Proper Citation: BD Biosciences Cat# 564017, RRID:AB_2738543

Target Antigen: CD279 (PD-1)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD279 (PD-1)

Description: This monoclonal targets CD279 (PD-1)

Target Organism: human

Clone ID: EH12.1 (also known as EH12)

Antibody ID: AB_2738543

Vendor: BD Biosciences

Catalog Number: 564017

Record Creation Time: 20250819T221730+0000

Record Last Update: 20250820T014351+0000

Ratings and Alerts

No rating or validation information has been found for CD279 (PD-1).

No alerts have been found for CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mold JE, et al. (2024) Clonally heritable gene expression imparts a layer of diversity within cell types. *Cell systems*, 15(2), 149.

Wang X, et al. (2023) CD70-induced differentiation of proinflammatory Th1/17/22/GM lymphocytes associated with disease progression and immune reconstitution during HIV infection. *Emerging microbes & infections*, 12(2), 2271068.

Cazzetta V, et al. (2021) NKG2A expression identifies a subset of human V α 2 T cells exerting the highest antitumor effector functions. *Cell reports*, 37(3), 109871.

Mold JE, et al. (2021) Divergent clonal differentiation trajectories establish CD8+ memory T cell heterogeneity during acute viral infections in humans. *Cell reports*, 35(8), 109174.

Fitzgerald B, et al. (2021) A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. *Cell reports methods*, 1(5).

Gu X, et al. (2021) Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes. *Journal of translational medicine*, 19(1), 26.